首页> 外文期刊>Recent patents on anti-cancer drug discovery >Mechanism of a Novel Camptothecin-Deoxycholic Acid Derivate Induced Apoptosis against Human Liver Cancer HepG2 Cells and Human Colon Cancer HCT116 Cells
【24h】

Mechanism of a Novel Camptothecin-Deoxycholic Acid Derivate Induced Apoptosis against Human Liver Cancer HepG2 Cells and Human Colon Cancer HCT116 Cells

机译:新型喜树碱 - 脱氧胆酸的机制衍生物诱导人肝癌HepG2细胞和人结肠癌HCT116细胞的细胞凋亡

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Camptothecin (CPT) is known as an anticancer drug in traditional Chinese medicine. However, due to the lack of targeting, low solubility, and instability of CPT, its therapeutic applications are hampered. Therefore, we synthesized a series of CPT-bile acid analogues that obtained a national patent to improve their tumour-targeting chemotherapeutic effects on liver or colon cancers. Among these analogues, the compound G2 shows high antitumor activity with enhanced liver targeting and improved oral absorption. It is significant to further investigate the possible anticancer mechanism of G2 for its further clinical research and application.
机译:背景:Camptothecin(CPT)被称为中医中的抗癌药物。 然而,由于缺乏靶向,低溶解性和CPT的不稳定性,其治疗应用受到阻碍。 因此,我们合成了一系列CPT-胆汁酸类似物,获得了国家专利,以改善其对肝脏或结肠癌的肿瘤靶向的化学治疗作用。 在这些类似物中,化合物G2显示出高抗肿瘤活性,具有增强的肝靶向和改善的口腔吸收。 进一步研究G2的可能抗癌机制是重要的,因为其进一步的临床研究和应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号